The weekly litigation news digest is live. Subscribe now

IP Verse

Novel Pharmaceutical Formulation Comprising Dual Nk-1/Nk-3 Receptor Antagonists - EP3765024

The patent EP3765024 was granted to Kandy Therapeutics on Nov 22, 2023. The application was filed on Mar 13, 2019 under application number EP19711866A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3765024

KANDY THERAPEUTICS
Application Number
EP19711866A
Filing Date
Mar 13, 2019
Status
Granted And Under Opposition
Oct 20, 2023
Publication Date
Nov 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
AERAAug 5, 2024AERAADMISSIBLE
AERAAug 5, 2024BARDEHLE PAGENBERG SLADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8093242
DESCRIPTIONWO2007028654
DESCRIPTIONWO2011023733
DESCRIPTIONWO2016184829
INTERNATIONAL-SEARCH-REPORTWO2011023733

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents